| abstract |
The present invention provides a heterocyclic pyrimidine derivative having an activity of regulating epidermal growth factor receptor (EGFR) kinase and ALK kinase. More specifically, the heterocyclic pyrimidine derivatives disclosed in the present invention can inhibit, modulate or modulate kinase receptors, particularly to selectively modulate the activity of various EGFR mutants or ALKs, and the present invention also discloses A pharmaceutical composition of a cyclic pyrimidine derivative, and a method of treating a disease associated with protein kinase activity, particularly EGFR and/or ALK kinase activity, by administering the heterocyclic pyrimidine derivative, including non-small cell lung cancer. |